BioCryst Pharmaceuticals, Inc.（BCRX）财务数据BCRXBioCryst Pharmaceuticals, Inc.

Evaluating the bottom line, BioCryst Pharmaceuticals, Inc. maintains a gross margin of 98.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 45.12%, while the net margin is 35.92%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BCRX converts its operational activities into shareholder value.

In the context of the broader market, BCRX competes directly with industry leaders such as PGEN and PHVS. With a market capitalization of $2.49B, it holds a leading position in the sector. When comparing efficiency, BCRX's gross margin of 98.24% stands against PGEN's 94.90% and PHVS's N/A. Such benchmarking helps identify whether BioCryst Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

BioCryst has demonstrated significant revenue growth, with total revenue increasing from 117 million USD in Q3 2024 to 218 million USD in Q2 2026. The gross margin remains strong, averaging around 97% over recent quarters, indicating effective cost management.